Proteomics analysis of colon cancer progression

Saira Saleem1*, Sahrish Tariq1, Iffat Aleem1, Sadr-ul Shaheed2, Muhammad Tahseen2, Ariba Atiq3, Sadia Hassan4, Muhammad Abu Bakar5, Shahid Khattak5, Aamir Ali Syed6, Asad Hayat Ahmad3, Mudassar Hussain3, Muhammed Aasim Yusuf7 and Chris Sutton2

Abstract

Background: The aim of this pilot study was to identify proteins associated with advancement of colon cancer (CC).

Methods: A quantitative proteomics approach was used to determine the global changes in the proteome of primary colon cancer from patients with non-cancer normal colon (NC), non-adenomatous colon polyp (NAP), non-metastatic tumor (CC NM) and metastatic tumor (CC M) tissues, to identify up- and down-regulated proteins. Total protein was extracted from each biopsy, trypsin-digested, iTRAQ-labeled and the resulting peptides separated using strong cation exchange (SCX) and reverse-phase (RP) chromatography on-line to electrospray ionization mass spectrometry (ESI-MS).

Results: Database searching of the MS/MS data resulted in the identification of 2777 proteins which were clustered into groups associated with disease progression. Proteins which were changed in all disease stages including benign, and hence indicative of the earliest molecular perturbations, were strongly associated with spliceosomal activity, cell cycle division, and stromal and cytoskeleton disruption reflecting increased proliferation and expansion into the surrounding healthy tissue. Those proteins changed in cancer stages but not in benign, were linked to inflammation/immune response, loss of cell adhesion, mitochondrial function and autophagy, demonstrating early evidence of cells within the nutrient-poor solid mass either undergoing cell death or adjusting for survival. Caveolin-1, which decreased and Matrix metalloproteinase-9, which increased through the three disease stages compared to normal tissue, was selected to validate the proteomics results, but significant patient-to-patient variation obfuscated interpretation so corroborated the contradictory observations made by others.

Conclusion: Nevertheless, the study has provided significant insights into CC stage progression for further investigation.

Keywords: Colon cancer, iTRAQ proteomics, Orbitrap fusion, Biomarkers

Introduction

Colorectal cancers (CRC) are the 3rd most common malignancies in the world. The global burden of CRC is expected to be more than 2.2 million new cases and 1.1 million deaths by 2030 [1]. In Asia, choice of unhealthy diet leading to obesity and metabolic syndrome, lack of public awareness on first choice of screening tests, poor public education for prevention, limited resources and support of healthcare authorities is resulting in increased susceptibility to CRC [2]. A positive relationship of family history, high fat diet, smoking and constipation exists among patients with a mean age of 41.47 ± 15.47 [3]. A cohort of 33 studies on over half a million subjects in the Asia-Pacific region concluded that other than body mass index and lack of physical activity (p < 0.05), height...
was strongly associated with CRC mortality such that an extra 5 cm in height was associated with 10% (95% confidence interval) additional risk, after adjustment for other factors. Diabetes and smoking increased the risk by 26% and 43%, respectively, while alcohol consumption, waist circumference and fasting blood glucose were not associated with CRC mortality [4].

Pakistan is situated in Southern Asia with distinct Punjabi, Sindhi, Pashtun, Baloch and Muhajir ethnic groups. The incidence of CRC is similar to developed Asian countries such as Japan, Republic of Korea and Singapore, but much lower than in Western developed countries [5]. Unfortunately, due to the absence of a national logging system for incidence, statistics on deaths due to cancers, survival rates cannot be estimated [6]. Information from individual health institutes, however, provides a valuable resource for Karachi, Sind [7], Rawalpindi and Punjab [8]. For example, the Cancer Registry at Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) operates to register cancer burden for the province of Punjab, and observed that CRC presents at an advanced stage and at a younger age (mean age 46.5 years) than other countries of similar wealth status [9]. The symptoms of CRC, such as rectal bleeding, persistent change in bowel habits, weight loss and continuous abdominal discomfort are often ignored due to embarrassment, but once addressed in a clinical environment are limited by the availability of doctors (7.8/10,000 population as per WHO observations) and resources (few screening centres in Punjab for a population of 30 million) to diagnose the disease through endoscopy and polyp histopathology. Consequently, a new front-line screening approach is required that can breakdown the cultural and economic barriers in Pakistan. The development of a biomarker-based diagnostic assay would enable greater acceptance of and accessibility to screening programs for CRC.

Colorectal cancer is a term used for the cancers of colon, rectosigmoid, rectum, anus and anal canal, which share similar histology however, distribution of cells and thickness of smooth muscles varies dependent on their function. Most of the pathology statistics are combined for CRC and do not provide regio-specific data. The colon is primarily responsible for the absorption of water and electrolytes while the rectosigmoid and rectum are for the storage of excreta for a short time. In SKMCH&RC, a total of 75,657 neoplasms (48.84% in males and 51.16% in females) primarily from Punjab were registered from 1994–2015, of which CRC ranked 5th most common (3530 cases) after breast cancer, leukemia, lip and oral cavity and non-Hodgkin’s lymphoma. Of the CRC cases 41.44% were colon cancers (964 in males and 499 in females), 7.19% were rectosigmoid (172 in males and 82 in females), rectal cancer 44.36% (1054 in males and 512 in females) and 6.99% of anus and anal canal (157 in males and 90 in females) (https://shaukatkhanum.org.pk/) [10].

Proteomics has been used previously to identify biomarkers of colorectal cancer though frequently using in vitro cell line models [11–13]. Those studies using biopsies often pooled samples from a number of patients from various sites (colon, rectum) and disease stages (metastatic and non-metastatic disease) to gain sufficient material for proteomics analysis. To support proteomics research of stage-specific (non-metastatic/node-negative and metastatic/node-positive) and site-specific (colon in our case) pooling of samples for specific protein profile, we pooled only colon tissues from exactly same stage (for non-metastatic colon cancer (CC NM). We pooled samples from patients who had primary disease in colon and were node-negative and for metastatic colon cancer (CC M), samples were pooled from patients who had tumors in colon and other organs (e.g. liver) of the body or were node-positive. Some studies have used matched, macroscopically normal margin around the borders of tumor for comparison of healthy and cancer tissues protein profiles, however, the margin may contain infiltrating tumor cells or cells in transition and therefore not be defined as normal tissue with certainty [14, 15]. For non-cancer (NC), we pooled colon lining tissues from non-cancer screening patients and for the benign, it was made sure that the patient has no malignancy.

One of the most complete studies to-date has been a label-free quantitative proteomics study of 64 colon cancer tissues and 31 rectum cancer tissues identifying 7526 proteins [16]. However, the molecular mechanisms underlying transformation of normal colon mucosa into malignancy and subsequent metastatic dissemination still remain unclear, and would benefit from a proteomics investigation of stage-specific disease development. To address this, and identify biomarkers indicative of disease progression, we performed a two-stage study. (a) iTRAQ-based proteomics analysis of disease progression using ethnically-, anatomically- and stage-specific, pooled colon biopsy protein extracts. (b) β-actin, Matrix metalloproteinase-9 (MMP-9) and caveolin-1 (CAV-1) western blot analysis of individual, stage-specific patient biopsies to compare with the proteomic analysis.

**Materials and methods**

**Patients and samples**

Ethical approval for this prospective study was obtained from the Institutional Review Board (registered with Office for Human Research Protections [OHRP], USA; IORG0004939) at SKMCH&RC, Lahore, Pakistan. A total of 98 tissue biopsies were obtained after getting consent
from patients undergoing screening colonoscopy and/or invasive surgery from 2015–2019. Resected specimens were grossed by a pathologist and preserved either by fixing in formalin for embedding into paraffin wax for histopathological diagnosis or stored fresh at −80 °C. The presence of cancer cells in the acquired specimen was confirmed independently by two clinical pathologists. For proteomic analysis, fresh frozen samples (n = 12) were selected from patients without prior chemotherapy and/or radiation and categorised as non-cancer, normal (NC), non-cancer non-adenomatous polyp (NAP), colon cancer; non-metastatic (CC NM) and colon cancer metastatic (CC M) (Additional file 1: Table S1a). For validation studies of selected targets, biopsies from an additional 86 patients without prior chemotherapy and/or radiation were collected (NC and NAP samples during colonoscopy and CC NM and CC M samples during surgery) for Western blot analysis (Additional file 1: Table S1b).

**Protein extraction**

The samples were processed under identical conditions. Tissue biopsies (5 mm³) from minimum of two patients for each type of sample (NC, NAP, CC NM and CC M) were pooled. The protein extraction method was adapted from a previously described dual lysis buffer approach [17]. Each specimen was first homogenized in RIPA lysis solution (50 μL, PBS pH 7.4, 0.25% sodium deoxycholate, 0.1% SDS containing EDTA-free protease inhibitor cocktail) followed by vortexing for 30 min at room temperature (RT) and sonicated on ice for 20 s using a Status US70 sonicating probe (Philips Harris Scientific, Hyde, UK). The samples were then centrifuged at 13,400 rpm for 20 min at 4 °C and liquid phase extracted to new tubes. Urea lysis buffer (50 μL, 7 M urea, 2 M thiourea, 4% w/v CHAPS, 50 mM DTT containing EDTA-free protease inhibitor cocktail) was added to the residual pellet, vortexed, sonicated and centrifuged as described above. The supernatant was combined with RIPA buffer extract. The urea lysis step was repeated on the residual pellet to extract all proteins giving a total volume of 200 μL. The protein concentration of samples was determined by Bradford assay (Sigma, Poole, UK). To a 70 μg aliquot of each protein extract, 1 mL of chilled acetone was added and allowed to precipitate overnight at −20 °C. The precipitated contents were centrifuged at 13,400 rpm for 20 min at 4 °C, the supernatant discarded and the pellet used for proteomics preparation.

**Peptide preparation and iTRAQ labelling**

Each protein precipitate (70 μg) was re-suspended in 8 M urea, reduced with 50 mM DTT for 20 min at 60 °C and then alkylated using 100 mM IAA for 20 min at RT, in the dark. Each mixture was diluted to reduce the urea concentration and digested with sequence grade trypsin (Roche Diagnostics, Burgess Hill, UK) (2.5 μL of 1 mg/mL prepared in 2 mM hydrochloric acid) was carried out overnight at 37 °C using a 1:10 trypsin-to-protein ratio (1:10 w/w). After digestion, peptide samples were lyophilized and re-suspended in 10 μL of 1 M tetraethylenammoniumborohydride (TEAB) containing 0.1% SDS. Each digest was incubated with an iTRAQ 4-plex reagent (SCIEX UK Limited, Warrington, UK)—NC with iTRAQ 114, NAP with 115, CC NM with 116 and CC M with 117 (Table 1), for 90 min at RT. HPLC grade water was added to stop the reaction. The labelled peptides were then pooled, desalted on an Isolute C18 RP column (Kinesis Ltd., St. Neots, UK) and the 80% CH3CN, 0.05% TFA eluate lyophilized. The pooled iTRAQ-labelled samples (Table 1) were fractionated on a SCX column (Isolute SPE column, Kinesis Ltd.) using stepwise elution with 0.03, 0.06, 0.09, 0.12, 0.15, 0.18, 0.24, 0.3, 0.5, 0.7 and 1 M KCl buffer. The fractions, including flow-through containing non-bound peptides, were desalted through C18 RP cartridges, lyophilized and stored at −20 °C.

**HPLC-ESI MS/MS**

The SCX fractions were analysed in duplicate on an Ultimate 3000 nano-HPLC—linked to an Orbitrap Fusion mass spectrometer (ThermoFisher, Hemel Hempstead, UK). Lyophilized fractions were resuspended in 0.1% formic acid (FA), 2 μL injected, and washed on a C18, 300 μm × 5 mm, 5 μm diameter, 100 Å Pep-Map precolumn (LC Packings, Sunnyvale, CA) before transfer to a C18, 75 μm × 50 cm, 2 μm diameter, 100 Å PepMap column (LC Packings) and peptides eluted with a linear gradient to 10–30% mobile phase B (80% acetonitrile, 0.1% FA) over 90 min, followed by 30–50% mobile phase B for 15 min. After washing in 90% solvent B for 10 min, the column was re-equilibrated for 20 min prior to the next injection. All data was acquired in data-dependent positive polarity mode with a spray voltage of 2200 V and ion transfer tube temperature of 275 °C. For MS, Orbitrap resolution was set at 120 K with scan range 350–1500 m/z, injection time of 50 ms. MS filter setting for parent ions; charge states from 2 to 7, dynamic exclusion duration was 70 and intensity threshold 5000. All MS/MS

| Table 1 Pooled protein extracts for iTRAQ 4-Plex labelling |
|----------------------|----------------------|-------|
| Pooled tissues from patients | Sample ID | iTRAQ label |
| n = 4 | Non-cancer normal colon lining (NC) | 114 |
| n = 2 | Non-adenomatous colon polyp (NAP) | 115 |
| n = 4 | Colon cancer (non-metastatic) (CC NM) | 117 |
| n = 2 | Colon cancer (metastatic) (CC M) | 116 |
data was acquired in the Ion Trap with a quadrupole isolation window 1.2, CID collision energy 35%, with maximum injection time of 50 ms and AGC target 10,000. iTRAQ quantification was performed through MS^3 in the Orbitrap; resolution of 30 K, mass range 110–500, 65% HCD collision energy and maximum ion injection time was 105 ms.

Database searching
Proteome Discoverer 2.1 software was used to process Orbitrap Fusion data, with Mascot version 2.4 (Matrix Science, London, UK) search engine against the Swiss-Prot database version 2016 (containing 552,259 human protein sequences). The search parameters used were: trypsin digestion, 2 missed cleavages, variable modification of methionine oxidation, fixed modifications of cysteine (carbamidomethylation) and iTRAQ (lysine and N-termini). A precursor mass tolerance of 10 ppm and fragmentation mass tolerance of 0.6 Da were selected. Non-redundant protein profiles were created by combining the search results from all 2D LC analyses using a confidence interval threshold set to a p-value<0.05 (equivalent to a Mascot score of ≥22), and filtered to include only Master Protein Candidates with 2 or more PSMs and at least one peptide with Mascot score ≥22 (FDR for peptide and protein searches was <1%). iTRAQ ratios were determined relative to the non-cancer control (NAP/NC−115/114, CC NM/NC−116/114, and CC M/NC−117/114). The median ratio for the total complement of proteins for each comparison was determined, the ratios of the individual proteins normalised, converted to log2. Significantly up-regulated and down-regulated proteins for each experimental condition (NAP/NC, NM/NC and M/NC) were defined as those with ratio>± standard deviation (SD) of log2 median. Protein-protein interactions analysis was performed using STRING (version 10.0, http://string-db.org/) for appreciably up- or down-regulated protein clusters.

Western blotting
Protein extracts from individual tissue biopsies were prepared using RIPA lysis buffer as described above [17], 10 µg protein of each were analysed individually by SDS-PAGE (Bio-Rad Mini Gel, Hercules, CA) on 10% polyacrylamide gels and electroblotted to a polyvinylidene fluoride (PVDF) membrane (Millipore; Immobilon-FL, 0.45-µm thickness) using a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) [18]. Blotted membranes were blocked with 5% skimmed milk solution in 20 mM Tris; pH 7.5, 150 mM NaCl, 0.1% Tween-20 (TBST) for 45 min at room temperature, incubated with primary antibody [anti-goat human CAV-1 (R&D Systems, Abingdon, UK, 1:2000 dilution), anti-mouse human MMP-9 (R&D Systems, Minneapolis, USA, 4:1000 dilution or rabbit anti-human β-Actin (Abcam, Cambridge, UK, 1:1000 dilution)] overnight at 4 °C and washed 3 times with TBST. Protein extracted from one biopsy, for which there was an adequate supply, was selected for inclusion on each blot to enable inter-experimental normalization. Blots were incubated with horseradish peroxidase (HRP)-conjugated secondary antibody [polyclonal donkey anti-goat (R&D Systems; 1:1000), HRP conjugated polyclonal goat anti-mouse (R&D Systems; 1:1000) or HRP conjugated polyclonal goat anti-rabbit (Abcam; 1:10,000)], respectively, washed 3 times with TBST and once with TBS (without Tween 20). Proteins were detected using ECL solution (GE Healthcare, Little Chalfont, UK) and chemiluminescent exposures captured on a Syngene (Cambridge, UK) GBOX using default settings.

Results
The main objective of this study was to look for proteins that play important biological roles in colon carcinogenesis and could be manipulated for their diagnostic value. Cancer patients were recruited based on TNM staging (Stage I, II, III, IV) in order to ascertain protein changes with disease progression (Table 1, Additional file 1: Table S1a). Stage I and II cancers are restricted to the primary site (colon) with no positive nodes and are referred to as non-metastatic (CC NM). In the case of stage III regional lymph nodes showed positivity for the presence of malignant cells confirming the disease spread while stage IV patients show malignant cells in secondary nearby organs as well. Both stage III and stage IV were referred to as metastatic (CC M), but all samples were taken from the primary tumors. We were also occasionally able to procure non-cancer normal colon tissues for comparison with matched NAP sample. The non-cancer status of the patients was confirmed by screening colonoscopy, taking a part of normal colon lining followed by its histopathology reports. Non-cancer patients were selected as a control group as there was less likelihood of mutated genes and the functional proteins would represent healthy profiles for comparisons with molecular signatures for cancer tissues. Tissue biopsies (5 mm³) from minimum of two patients for each type of sample (NC, NAP, CC NM and CC M) were pooled, from which an average of 70 µg of protein was extracted for proteomics analysis.

A total list of 2777 non-redundant proteins were detected with 2 PSMs, of which 2768 had 2 iTRAQ values (Additional file 2: Table S2), PProteomics IDEnifications (PRIDE) PXD. Protein iTRAQ ratios were normalized to enable stage-related comparisons (NAP/NC, CC NM/NC and CC M/NC), and significantly up- and down-regulated proteins (+/− 1 log2, standard
deviation respectively) were identified (Table 2). Proteins were clustered into 27 groups based in increased (I), unchanged (U) or decreased (D) for each of the three disease stages relative to normal colon, NAP/NC, CC NM/NC and CC M/NC. This analysis provided groups of protein associated with disease progression. As would be expected, the largest cluster comprising 59% of the total protein complement (Fig. 1, Cluster C14, UUU) exhibited no significant change in any of the three disease stages suggesting no roles in oncogenic processes or are modified post-translationally rather than via transcriptional activation/deactivation. Other clusters containing a large complement of proteins were those indicative of disease progression (Fig. 1). For example, 125 proteins were increased in all stages (Cluster 27, III, Fig. 1) relative to the NC control, representing early expression changes in colon cancer initiation and were sustained through to metastatic disease (Fig. 1). Whereas 121 proteins were increased in cancer tissues (CC NM and CC M, Cluster 18, UII, Fig. 1) which were associated with cancer progression and 78 increased only in the metastatic stage which were responsible for later oncogenic events (Cluster 15, UUI, Fig. 1). Encouragingly, the smallest clusters or those with no proteins, were those associated with sporadic responses, for example DDI (Cluster 3, Fig. 1) decreased in NAP and CC NM but increased in CC M). Within the main clusters, many of the proteins that changed in expression demonstrated functional importance, which were analysed by STRING analysis.

Proteins changed in all stages of disease progression (clusters III and DDD)

There was a significant up-regulation of RNA metabolism and spliceosome-associated protein expression ($p = 6.12 \times 10^{-15}$), cell cycle division proteins (cell division cycle 5-like protein, cell division cycle and apoptosis regulator protein 1, nuclear autoantigenic sperm protein, acidic leucine-rich nuclear phosphoprotein 32 family member A and B), and chromatin folding/remodeling proteins (high mobility group protein A1, B1, B2 and B3 isoforms and SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1) in all stages (III) relative to non-cancer indicative of enhanced replication, transcription and translation leading to cell proliferation in colon cancer stages (Additional file 3: Figure S1(i), Table 3a). Similarly STRING analysis of the proteins decreased in all disease stages (DDD) were very strongly associated with extracellular matrix organization ($p = 8.86 \times 10^{-20}$) (Additional file 3: Figure S1(ii), Table 3b). Of particular note, 10 of the 17 collagen isoforms detected were decreased in all stages of colon malignancy and 6 others showing evidence of reduction compared to normal tissue. The DDD cluster were also associated with cytoskeleton disruption (e.g. tropomyosin alpha-1, tropomyosin beta, tubulin beta-2A, myosin light polypeptide 6, myosin regulatory light polypeptide 9, myosin-11, filament-C, desmin, smoothelin, leiomodin-1 and peripheral plasma membrane protein CASK) correlating

### Table 2 Cluster analysis according to observed response modes of proteins in each of the diseased states relative to normal non-cancer tissue

| Group | Response | No. of proteins | PPI enrichment, p-value |
|-------|----------|----------------|-------------------------|
| 1     | DDD      | 142            | $< 1.0 \times 10^{-16}$ |
| 2     | DDU      | 89             | $1.37 \times 10^{-06}$  |
| 3     | DDI      | 5              | 1                       |
| 4     | DUD      | 25             | $1.32 \times 10^{-09}$  |
| 5     | DUU      | 93             |                         |
| 6     | DUI      | 5              | 1                       |
| 7     | DID      | 0              |                         |
| 8     | DII      | 0              |                         |
| 9     | DII      | 2              | 1                       |
| 10    | UDD      | 198            | $< 1.0 \times 10^{-16}$ |
| 11    | UDU      | 56             | $2.81 \times 10^{-05}$  |
| 12    | UUD      | 64             | $2.83 \times 10^{-12}$  |
| 13    | UDU      | 0              |                         |
| 14    | UUU      | 1636           | $1.00 \times 10^{-16}$  |
| 15    | UUI      | 78             | $3.86 \times 10^{-05}$  |
| 16    | UID      | 0              |                         |
| 17    | UIU      | 48             | $4.25 \times 10^{-09}$  |
| 18    | UII      | 121            | $1.00 \times 10^{-16}$  |
| 19    | UDD      | 5              | 1                       |
| 20    | IDD      | 0              |                         |
| 21    | IDU      | 0              |                         |
| 22    | IID      | 2              | 1                       |
| 23    | IUU      | 104            | $1.03 \times 10^{-16}$  |
| 24    | IUU      | 16             | $2.80 \times 10^{-05}$  |
| 25    | IID      | 0              |                         |
| 26    | IID      | 12             | 0.477                   |
| 27    | III      | 125            | $< 1.0 \times 10^{-16}$ |

Italic values indicate significance of p-values ($p < 0.05$). This means that proteins in the same group have enriched interactions indicating these are partially biologically connected.
with various structural changes in colon during disease progression, such as loss of cell contour associated with cell transformation and metastasis (Table 3b, Additional file 3: Figure S1(ii)). In addition, proteins responsible for colon mucosal function relating to excretion, transport of metabolites and modification of xenobiotics (UDP-glucuronosyltransferase isoforms) are decreased, indication that the cells no longer function for their intended purpose in the colon.

An increase in serine proteases HTRA3, myeloblastin and lactotransferrin in all stages and metalloproteinases (MMP-9, ADAMTS4 and neutrophil elastase) in CC NM and CC M, supports degradation of the stroma surrounding the tissues as the tumor progresses. The action of these proteases may inhibit TGF-beta signaling indirectly through degradation of proteoglycans.

Protein changes in malignant stages of the colon cancer (CC NM and CC M, clusters UII and UDD)

In addition to matrix acting proteases, proteins increased in the cancer cluster (UII) were associated with inflammation/immune response and antimicrobial activity (neutrophil defensin 1 and 4, fibrinogen alpha, beta and gamma chains, prothrombin, protein S100-A8 and A9, cathepsin E, coiled-coil domain-containing protein 88B), cytoskeletal re-modelling (nesprin-1, fascin, actin-related protein 2/3 complex subunit 4), allograft inflammatory factor 1, plasmin-2, macrophage-capping protein, neurabin-2, calponin-2, twinfilin-1, brain-specific angiogenesis inhibitor 1-associated protein 2, serine/threonine-protein kinase PAK 2) and 15 proteins involved in ubiquitin-linked protein degradation (Fig. 2a).
Table 3 (a) Functionally significant proteins increased in all stages of disease or in cancer stages (III, UII) (b) Functionally significant proteins decreased in all stages of disease or in both cancer stages (DDD, UDD). Significantly changed expression (± 1SD) in italic cells

| Accession | Description | Gene | MW (kDa) | Calc. pI | Mascot score | Peptides Mascot | Coverage % | NAP/NC log2 | CC NM/NC log2 | CC M/NC log2 |
|-----------|-------------|------|----------|---------|-------------|----------------|-----------|-------------|--------------|--------------|
| a         | Cell cycle progression, proliferation, DNA folding | CDC5L | 92.194 | 8.18 | 41 | 2 | 3 | 3.82 | 2.18 | 3.98 |
|           |             | CCAR1 | 132.739 | 5.76 | 106 | 3 | 3 | 2.16 | 2.16 | 2.42 |
|           |             | NASP  | 85.186 | 4.3 | 300 | 5 | 10 | 1.32 | 1.84 | 2.43 |
|           |             | ANP32A | 28.568 | 4.09 | 232 | 2 | 14 | 1.67 | 2.06 | 2.34 |
|           |             | ANP32B | 28.770 | 4.06 | 367 | 2 | 14 | 2.15 | 2.76 | 3.09 |
|           |             | HMGB1 | 24.878 | 5.74 | 1254 | 9 | 40 | 1.74 | 2.27 | 2.80 |
|           |             | HMGB2 | 24.019 | 7.81 | 1066 | 7 | 25 | 1.71 | 2.09 | 2.89 |
|           |             | HMGB3 | 22.965 | 8.37 | 450 | 4 | 28 | 1.43 | 1.74 | 2.52 |
|           |             | HMGA1 | 11.669 | 10.32 | 213 | 2 | 33 | 3.78 | 3.65 | 3.85 |
|           |             | SMARCE1 | 46.621 | 4.88 | 56 | 1 | 3 | 1.80 | 2.37 | 3.16 |
| Matrix degradation | Serine protease HTRA3 | HTRA3 | 48.577 | 7.09 | 61 | 1 | 3 | 1.31 | 1.74 | 2.83 |
|           | Neutrophil gelatinase-associated lipocalin | LCN2 | 22.574 | 8.91 | 417 | 3 | 23 | 1.34 | 2.14 | 3.18 |
|           | Myeloblastin | PRTN3 | 27.789 | 8.35 | 658 | 4 | 28 | 1.26 | 3.79 | 3.50 |
|           | Lactotransferrin | LTF | 78.132 | 8.12 | 3542 | 30 | 49 | 1.72 | 2.52 | 4.19 |
|           | Matrix metalloproteinase-9 | MMP9 | 78.408 | 6.06 | 358 | 6 | 10 | 0.68 | 3.38 | 3.69 |
|           | A disintegrin and metallopeptinase with thrombospondin motifs 4 | ADAMTS4 | 90.139 | 7.85 | 26 | 1 | 1 | 0.60 | 1.90 | 2.90 |
|           | Neutrophil elastase | ELANE | 28500 | 9.35 | 665 | 8 | 42 | −0.03 | 1.87 | 2.82 |
| Cytoskeletal remodelling | Nesprin-1 | SYNE1 | 101046 | 5.53 | 41 | 3 | 0 | −1.00 | 1.80 | 3.14 |
|           | Fascin | FSCN1 | 54.496 | 7.24 | 339 | 6 | 14 | −0.37 | 1.84 | 3.24 |
|           | Actin-related protein 2/3 complex subunit 4 | ARPC5 | 196.54 | 8.43 | 89 | 2 | 10 | −0.23 | 1.61 | 2.54 |
|           | Allograft inflammatory factor 1 | AIF1 | 16.693 | 6.24 | 566 | 1 | 14 | −0.19 | 2.04 | 2.69 |
|           | Protein S100-A8 | S100A8 | 10.828 | 7.03 | 2582 | 8 | 72 | 0.00 | 3.76 | 2.38 |
|           | Protein S100-A9 | S100A9 | 13.234 | 6.13 | 6645 | 7 | 63 | 0.19 | 4.05 | 2.45 |
|           | Plastin-2 | LCP1 | 70.244 | 5.43 | 1803 | 15 | 40 | 0.27 | 2.68 | 2.07 |
|           | Macrophage-capping protein | CAPG | 38.474 | 6.19 | 1382 | 9 | 35 | 0.33 | 2.00 | 3.07 |
|           | Neurabin-2 | PPP1R9B | 89.138 | 4.97 | 35 | 1 | 1 | 0.69 | 1.73 | 3.42 |
Table 3 (continued)

| Accession | Description | Gene | MW (kDa) | Calc. pI | Mascot score | Coverage % | Peptides | NAP/NC log2 | CC NM/NC log2 | CC M/NC log2 |
|-----------|-------------|------|----------|----------|--------------|------------|----------|-------------|---------------|---------------|
| Q99439    | Calponin-2  | CNN2 | 33.675   | 7.33     | 668          | 5          | 24       | 0.75       | 2.06          | 2.46          |
| Q12792    | Twinfilin-1 | TWF1 | 40.258   | 6.96     | 40           | 2          | 12       | 0.80       | 2.04          | 2.35          |
| Q9UQ88    | Brain-specific angiogenesis inhibitor 1-associated protein 2 | BAIA2 | 60.830   | 8.9      | 73           | 1          | 3        | 0.89       | 2.41          | 2.46          |
| Q13177    | Serine/threonine-protein kinase PAK 2 | PAK2 | 58.006   | 5.96     | 173          | 3          | 16       | 1.09       | 1.88          | 2.23          |

Immunity/inflammation

| Accession | Description | Gene | MW (kDa) | Calc. pI | Mascot score | Coverage % | Peptides | NAP/NC log2 | CC NM/NC log2 | CC M/NC log2 |
|-----------|-------------|------|----------|----------|--------------|------------|----------|-------------|---------------|---------------|
| P02671    | Fibrinogen alpha chain | FGA  | 94.914   | 6.01     | 2948         | 17         | 19       | −0.57      | 2.36          | 3.84          |
| P02675    | Fibrinogen beta chain | FGB  | 55.892   | 8.27     | 4950         | 28         | 61       | −0.95      | 2.19          | 3.20          |
| P02679    | Fibrinogen gamma chain | FGG  | 51.479   | 5.62     | 2304         | 18         | 49       | −0.96      | 2.66          | 3.28          |
| P59665    | Neutrophil defensin 1 | DEFA1 | 10.194   | 6.99     | 358          | 2         | 19       | 0.34       | 2.01          | 2.54          |
| P12838    | Neutrophil defensin 4 | DEFA4 | 10.497   | 8.02     | 54           | 1         | 18       | 1.19       | 2.21          | 2.44          |

Extracellular matrix

| Accession | Description | Gene | MW (kDa) | Calc. pI | Mascot score | Coverage % | Peptides | NAP/NC log2 | CC NM/NC log2 | CC M/NC log2 |
|-----------|-------------|------|----------|----------|--------------|------------|----------|-------------|---------------|---------------|
| Q96P44    | Collagen alpha-1(XXI) chain | COL21A1 | 99.307   | 8.32     | 76           | 1          | 1        | −3.27      | −5.81         | −6.30         |
| P02462    | Collagen alpha-1(IV) chain | COL4A1 | 160.514  | 8.28     | 1483         | 6          | 5        | −2.70      | −2.71         | −2.94         |
| P39060    | Collagen alpha-1(VIII) chain | COL18A1 | 178.077  | 6.01     | 395          | 3          | 2        | −0.00      | −3.09         | −2.75         |
| P08572    | Collagen alpha-2(IV) chain | COL4A2 | 167.449  | 8.66     | 1983         | 13         | 12       | −2.18      | −2.71         | −2.80         |
| P08123    | Collagen alpha-2(I) chain | COL1A2 | 129.235  | 8.95     | 2714         | 9          | 8        | −2.62      | −2.44         | −2.56         |
| P02452    | Collagen alpha-1(I) chain | COL1A1 | 138.857  | 5.80     | 1814         | 9          | 9        | −2.92      | −1.95         | −2.37         |
| Q05707    | Collagen alpha-1(XIV) chain | COL14A1 | 193.394  | 5.30     | 894          | 20         | 16       | −2.52      | −2.55         | −2.16         |
| Q14031    | Collagen alpha-6(IV) chain | COL4A6 | 163.704  | 9.20     | 135          | 1          | 1        | −0.61      | −2.46         | −3.94         |
| P12111    | Collagen alpha-3(VI) chain | COL6A3 | 343.457  | 6.68     | 21068        | 100        | 41       | −1.81      | −2.20         | −2.44         |
| P12110    | Collagen alpha-2(VI) chain | COL6A2 | 108.512  | 6.21     | 5018         | 24         | 29       | −2.15      | −1.85         | −1.99         |
| P12109    | Collagen alpha-1(VI) chain | COL6A1 | 108.462  | 5.43     | 6769         | 25         | 37       | −1.87      | −2.00         | −2.09         |
| P20908    | Collagen alpha-1(V) chain | COL5A1 | 153.947  | 5.06     | 29           | 2          | 2        | −0.18      | −2.20         | −2.24         |
| Q16363    | Laminin subunit alpha-4 | LAMA4 | 202.397  | 6.28     | 475          | 12         | 10       | −2.72      | −2.05         | −1.98         |
| Q15230    | Laminin subunit alpha-5 | LAMA5 | 399.749  | 7.02     | 1735         | 28         | 11       | −2.89      | −3.34         | −2.30         |
| P55268    | Laminin subunit beta-2 | LAMB2 | 195.854  | 6.52     | 1451         | 27         | 23       | −2.88      | −3.28         | −2.42         |
| P13727    | Bone marrow proteoglycan | PRG2 | 25.189   | 6.76     | 637          | 5          | 30       | −1.37      | −2.85         | −4.55         |
| Q6UVK1    | Chondroitin sulfate proteoglycan 4 | CSPG4 | 250.382  | 5.47     | 134          | 2         | 2        | −1.14      | −2.98         | −2.95         |
| Q9Y2V8    | Proteoglycan 3 | PRG3 | 25.389   | 4.81     | 222          | 3          | 16       | −0.33      | −2.93         | −2.41         |
| P07585    | Decorin 1 | DCN  | 39.722   | 8.54     | 1574         | 13         | 51       | −2.66      | −4.53         | −3.85         |
| P21810    | Biglycan | BGN  | 41.628   | 7.52     | 1834         | 11         | 46       | −1.73      | −1.91         | −1.89         |
| Accession | Description                                           | Gene   | MW (kDa) | Calc. pI | Mascot score | Coverage % NAP/NC log2 | CC NM/NC log2 | CC M/NC log2 |
|-----------|-------------------------------------------------------|--------|----------|----------|--------------|------------------------|--------------|--------------|
| P14543    | Nidogen-1                                             | NID1   | 136.291  | 5.29     | 904          | 15                     | 17           | −2.65        |
| Q14112    | Nidogen-2                                             | NID2   | 151.158  | 5.29     | 640          | 11                     | 13           | −1.56        |
| P35613    | Basigin                                               | BSG    | 42.174   | 5.66     | 319          | 5                      | 18           | −1.71        |
| P08648    | Integrin alpha-5                                       | ITGA5  | 114.465  | 5.77     | 678          | 10                     | 13           | −2.26        |
| P05556    | Integrin beta-1                                        | ITGB1  | 88.357   | 5.39     | 3088         | 16                     | 25           | −1.21        |
| P18084    | Integrin beta-5                                        | ITGB5  | 87.996   | 6.06     | 225          | 3                      | 4            | −1.28        |
| P23229    | Integrin alpha-6                                       | ITGA6  | 126.526  | 6.61     | 1739         | 23                     | 25           | 0.18         |
| P27216    | Annexin A13                                            | ANXA13 | 35.393   | 5.60     | 251          | 3                      | 9            | −1.57        |
| P20073    | Annexin A7                                             | ANXA7  | 52.706   | 5.68     | 225          | 3                      | 8            | −1.69        |
| P08133    | Annexin A6                                             | ANXA6  | 75.826   | 5.60     | 3275         | 30                     | 50           | −2.02        |
| P13688    | Carcinoembryonic antigen-related cell adhesion molecule 1 | CEACAM1 | 57.525   | 5.97     | 148          | 2                      | 6            | −2.64        |
| P14002    | Carcinoembryonic antigen-related cell adhesion molecule 7 | CEACAM7 | 29.361   | 5.54     | 335          | 2                      | 12           | −2.05        |
| P09326    | CD48 antigen                                            | CD48   | 27.665   | 8.07     | 90           | 2                      | 10           | −1.39        |
| P13987    | CD59 glycoprotein                                       | CD59   | 14.168   | 6.48     | 428          | 4                      | 25           | −0.88        |
| P08962    | CD63 antigen                                            | CD63   | 25.619   | 7.81     | 74           | 1                      | 9            | −0.48        |
| P60033    | CD81 antigen                                            | CD81   | 25.792   | 5.29     | 184          | 3                      | 25           | −1.27        |
| P21926    | CD9 antigen                                             | CD9    | 25.399   | 7.15     | 475          | 3                      | 21           | 0.09         |
| Q99755    | Cell surface A33 antigen                                | GPA33  | 35.609   | 4.93     | 694          | 9                      | 37           | −0.72        |
| P04323    | HLA class II histocompatibility antigen gamma chain     | CD74   | 33.494   | 8.44     | 296          | 3                      | 9            | −0.17        |
| P28907    | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1       | CD38   | 34.306   | 7.66     | 302          | 6                      | 23           | −0.21        |
| P04899    | Guanine nucleotide-binding protein G(i) subunit alpha-2  | GNA12  | 40.425   | 5.54     | 1216         | 10                     | 36           | −1.55        |
| Q9UB16    | Guanine nucleotide-binding protein G(i) subunit gamma-12 | GNG12  | 8001     | 8.97     | 31           | 1                      | 26           | −0.11        |
| P62873    | Guanine nucleotide-binding protein G(i) subunit beta-1  | GN1    | 37.353   | 6.00     | 761          | 6                      | 26           | −0.76        |
| P62879    | Guanine nucleotide-binding protein G(i) subunit beta-2  | GN2    | 37.307   | 6.00     | 527          | 6                      | 26           | −1.01        |
| P29992    | Guanine nucleotide-binding protein subunit alpha-11     | GNA11  | 420.97   | 5.69     | 364          | 3                      | 15           | −1.60        |
| Q14344    | Guanine nucleotide-binding protein subunit alpha-13     | GNA13  | 440.22   | 8.00     | 525          | 3                      | 7            | −1.43        |
| Accession | Description                                                                 | Gene | MW (kDa) | Calc. pI | Mascot score | Coverage % | NAP/NC log2 | CC NM/NC log2 | CC M/NC log2 |
|-----------|-----------------------------------------------------------------------------|------|----------|----------|--------------|------------|-------------|---------------|-------------|
| O75795    | UDP-glucuronosyltransferase 2B17                                            | UGT2B17 | 61.055   | 8.54     | 895          | 14         | -6.21       | -4.49         | -5.67       |
| P40879    | Chloride anion exchanger                                                   | SLC26A3 | 84.451   | 8.69     | 91           | 3          | -4.01       | -4.36         | -4.89       |
| Q6UWM9    | UDP-glucuronosyltransferase                                                 | UGT2A3 | 60.215   | 7.96     | 234          | 4          | 10          | -3.88         | -6.25       |
| Q14CN2    | Calcium-activated chloride channel regulator                                | CLCA4 | 4        | PE=1     | 150V1=219    | 274        | 5           | 6             | -3.59       |
| P54289    | Voltage-dependent calcium channel subunit alpha-2/delta-1                   | CACNA2D1 | 124.49   | 5.27     | 59           | 2          | 3           | -2.55         | -4.72       |
| P50443    | Sulfate transporter                                                        | SLC26A2 | 81.609   | 8.38     | 102          | 2          | 4           | -2.16         | -2.58       |
| Q96K5A5   | Cleft lip and palate transmembrane protein 1-like protein                  | CLPTM1L | 62.189   | 8.56     | 68           | 3          | 8           | -2.13         | -3.85       |
| O15438    | Canalicular multispecific organic anion transporter 2                       | ABCC3 | 169.234  | 7.20     | 46           | 1          | 1           | -1.95         | -2.72       |
| Q15041    | ADP-ribosylation factor-like protein 6-interacting protein 1               | ARL6P1 | 23.347   | 9.32     | 27           | 1          | 5           | -1.69         | -2.03       |
| O14936    | Periphera plasma membrane protein CASK                                    | CASK  | 105.056  | 6.43     | 28           | 1          | 1           | -1.58         | -1.97       |
| P20020    | Plasma membrane calcium-transporting ATPase 1                             | ATP2B1 | 138.668  | 6.04     | 123          | 5          | 4           | -1.38         | -2.29       |
| P16662    | UDP-glucuronosyltransferase 2B7                                             | UGT2B7 | 60.655   | 8.31     | 618          | 3          | 7           | -1.36         | -3.71       |
| P10301    | Ras-related protein R-Ras                                                  | RRAS  | 23.466   | 6.93     | 217          | 3          | 15          | -1.32         | -3.18       |
| Q8NE86    | Calcium uniporter protein, mitochondrial                                   | MCU   | 39.842   | 8.65     | 181          | 5          | 16          | -1.32         | -2.48       |
| Q6UWW8    | Carboxylesterase 3                                                         | CES3  | 62.242   | 5.62     | 137          | 3          | 10          | -0.46         | -1.80       |
| P23141    | Liver carboxylesterase 1                                                   | CES1  | 62.481   | 6.60     | 81           | 2          | 4           | -2.12         | -1.78       |
| P50225    | Sulfotransferase 1A1                                                       | SULT1A1 | 34.143   | 6.62     | 187          | 1          | 13          | -3.21         | -3.38       |
| P0DMN0    | Sulfotransferase 1A4                                                        | SULT1A4 | 34.174   | 6.01     | 240          | 2          | 17          | -0.97         | -1.25       |
| P07099    | Epoxide hydrolase 1                                                        | EPHX1 | 52.915   | 7.25     | 280          | 6          | 17          | -2.41         | -2.29       |
| P37059    | Estradiol 17-beta-dehydrogenase 2                                           | HSD17B2 | 42.757   | 8.50     | 57           | 1          | 4           | -2.52         | -3.78       |
| Q92506    | Estradiol 17-beta-dehydrogenase 8                                           | HSD17B8 | 26.957   | 6.54     | 402          | 4          | 20          | 0.57          | -1.91       |
| P80355    | Corticosteroid 11-beta-dehydrogenase isozyme 2                            | HSDB11B2 | 44.098   | 9.28     | 453          | 6          | 22          | -2.35         | -3.66       |
Those proteins that were decreased in cancer stages but not benign (UDD, PPI enrichment \( p < 1.0 \times 10^{-16} \)), were noticeable associated with mitochondrial function affecting electron transport and the respiratory chain, citric acid cycle, ATP synthase, mitochondrial ribosomes and DNA replication, ADP/ATP transport and other metabolite trafficking (Fig. 2b). Overall this suggests a decrease in mitochondria composition within colon cancer cells (FDR = 1.67E − 10). Glucagon was also one of the proteins increased in this group. Increased glucagon can result in hepatic gluconeogenesis contributing to metabolic syndrome cancer cachexia [19] leading to negative energy balance [20], weight loss and reduced food intake [21]. Elevated glucagon promotes release of glucose which stimulates tumor protein synthetic rate to double in colorectal cancer [22].

A group of proteins decreased in colon cancer non-metastatic and metastatic stages were associated with plasma membrane function indicating loss of cell–cell adhesion, cell junctions and cell-matrix interaction which was already in evidence in benign disease in the form of decreased G-protein-linked transmembrane signaling. Isoforms of G protein alpha, beta and gamma subunits, integrin alpha and beta subunits (\( \alpha_1, \alpha_3, \alpha_5, \alpha_7, \beta_1 \) and \( \beta_3 \)) and annexins (A1, A2, A4, A5, A6, A7, A11 and A13) exhibited a reduction in levels indicating a suppression of membrane

Fig. 2  

- STRING analysis of proteins increased in non-metastatic and metastatic stages of colon cancer (UII).
- STRING analysis of proteins decreased in non-metastatic and metastatic stages of colon cancer (UDD). Proteins are shown as nodes and the color of each link defined the type of evidence available for the interaction between two proteins (e.g. blue: co-occurrence, black: co-expression, purple: experimental, aqua: databases, green: text mining and light blue is homology.)
signal transduction (see Table 3b). Integrins are stimulators of cancer cell proliferation and tumor angiogenesis [23] linked to the Ras-ERK pathway by CAV-1, tyrosine kinase Fyn and Shc [24] and integrin alpha-1 expression is directly regulated by oncogenic factor c-MYC [25]. N-Ras and R-Ras were both decreased in our proteomics dataset, along with proteins associated with transport vesicle and caveolae formation, including CAV-1.

Protein changes in later stage of the colon cancer (CC M, clusters UUI and UUD)

Those protein uniquely increased in tumors that have advanced to a metastatic stage (UUI, 78 proteins), indicating an escalation of immune/inflammation response (complement component C6, factor H, syntenin-1, apoptosis-associated speck-like protein containing a CARD, protein canopy homolog 3) and ubiquitin-associated protein turnover (ubiquitin-conjugating enzyme E2 N, ubiquitin-1, -2 and -4, TP53-binding protein 1 and centrosomal protein of 131 kDa). Ubiquilin proteins play a role in LC3-mediated production of autophagosomes, a process indicative of the harsh microenvironment of solid tumors starved of oxygen and nutrients, from which select cancer cell may well survive to spread by metastasis (Additional file 3: Figure S1 (iii)) [26].

Those proteins decreased only in late stage colon cancer indicated further losses in mitochondrial function and membrane transport activity (Additional file 3: Figure S1(iv)). In addition, mucin-2, which is a highly abundant component of colon mucus layers was decreased and suggestive of a massive disruption of normal tissue morphology as these advanced tumors invade the surrounding organs. Interestingly, there was an inverse response in the expression of mucin-5AC, which is normally detected in gastric and respiratory tract mucosa.
Protein signatures specifically related to benign disease (NAP, clusters IUU and DUU)

Increased protein signatures, uniquely associated with benign disease (non-adenomatous polyps) were strongly coupled with transcriptional (spliceosomal) and translational processing (ribosomal) (FDR = 8.13E−25) (Additional file 3: Figure S1(v)). No clear functional profiles was derived from the analysis of the decreased proteins, though many components were linked to neutrophil degranulation (FDR = 4.01E−07) (Additional file 3: Figure S1(vi)).

Caveolin-1 and MMP-9 expression

We aimed to validate a protein identified with as low as ≤10 peptides in our ESI-MS data and had already been associated with colon cancer progression. So we selected caveolin-1 (CAV-1) from the cluster C10 (Fig. 1) UDD (unchanged between benign and non-cancer tissues but decreased in both non-metastatic and metastatic and tumor as compared to non-cancer tissues) and Matrix metalloproteinase-9 (MMP-9) from the cluster C18 (Fig. 1) UII (unchanged between benign and non-cancer tissues but increased in both non-metastatic and metastatic and tumor as compared to non-cancer tissues) for further investigation. In so doing we wished to determine if CAV-1 and MMP-9 have the potential to be a suitable biomarker. There is contradictory evidence of the expression changes of CAV-1 in different cancer tissues [27–31], yet clear pivotal role in different oncogenic processes. Although not used diagnostically, the role of MMP-9 has been well described in CRC invasion and metastasis, enabling tumor growth and cancer cells to escape into circulation [32–35].

We screened the expression of these proteins on discrete and unique patient samples ranging from tissues from non-cancer (screening patients) to benign/non-malignant polyps and poorly- to well-differentiated colon cancer tissues. We intended to analyse our patient population (Asian/Pakistani) and establish CAV-1 and MMP-9 significance in colon cancer.

CAV-1, MMP-9 and β-actin (loading control) were analysed by western blotting of protein extracts from an independent cohort of 86 patients with well characterized normal colon mucosa, benign polyps and tumors from stage I-IV tissues histopathologies (Fig. 3a, Additional file 4: Figure S2). Our results indicate CAV-1 is expressed in all tissue types in various degrees. Normal tissues from non-cancer patients (Fig. 3a: NC, NAP) expressed CAV-1 and MMP-9. The slight increase in expression of CAV-1 in CC NM I T compared to CC NM I N (Fig. 3a) shows a different response to that determined by proteomics analysis where a decrease in tumor was observed as compared to the non-cancer tissue (UDD).

However normal tissues from cancer patients (Fig. 3a: CC NM II N and CC M III N) expressed higher CAV-1 than the matched tumor tissues (Fig. 3a: CC NM II T and CC M III T). This decrease in CAV-1 expression in tumor tissue suggests that loss of CAV-1 is required for the disease to establish which relates to clinical outcome. Overall the findings of the study reflect patient-to-patient variations. This warrants further investigation to determine if CAV-1 is a biomarker of early colon cancer or an indicator of abnormal growth in colon mucosa. Analysis of the cohort (Fig. 3b, Additional file 5: Table S3a), indicates that the trend of expression of CAV-1 is increasing from NC to CC NM (p<0.038, Additional file 5: Table S3c), but then decreases in CC M. Similar properties for β-actin were observed. The MMP-9 (Fig. 3a) shows a similar response to that determined by proteomics analysis where an increase in tumor was observed as compared to the non-cancer tissue (UII). Tumor tissues from cancer patients (Fig. 3a: CC NM II T and CC M III T) expressed higher MMP-9 than the matched normal tissues (Fig. 3a: CC NM II N and CC M III N).
Discussion

Many of those proteins that were significantly changed in this investigation, have formerly been associated with colon cancer, including HLA class II histocompatibility antigen gamma chain (CD74) [36], carcinoembryonic antigen-related cell adhesion molecule-7 (CEACAM-7) [37], glutathione S-transferase omega-1 (GSTO1) [38], matrix metalloproteinase-9 (MMP-9) [35], hepatoma-derived growth factor (HDGF) [39], lactotransferrin (LTF) [40], cytoskeleton-associated protein 5 (also known as colonic tumor overexpressed gene protein) [41] and DNA (cytosine-5)-methyltransferase 1 [42]. CD74 was previously shown to be decreased in cancer samples based on mRNA levels (NAP/NC ratio log$_2$ $-0.169$, CC NM/NC $-1.966$ and CC M/NC $-2.601$) and CEACAM-7 (NAP/NC ratio log$_2$ $-2.054$, CC NM/NC $-3.259$ and CC M/NC $-3.911$) based on immunohistochemistry staining. GSTO1 expression was unchanged in non-adenomatous, but significantly elevated in non-metastatic and metastatic states (NAP/NC ratio log$_2$ $-0.222$, CC NM/NC 1.854 and CC M/NC 2.452). GSTO1 knock-down by the inhibitor C1-27 in colon cancer cell line HCT116 resulted in down-regulation of Dickkopf-related protein 1 (DKK1), thombospondin 1 (THBSS1) and CAV-1 [43]. MMP-9 (NAP/NC ratio log$_2$ 0.677, CC NM/NC 3.379 and CC M/NC 3.691), which is responsible for extracellular matrix degradation exhibited an even more profound response. Two anti-apoptotic proteins HDGF (NAP/NC ratio log$_2$ 1.349, CC NM/NC 2.237 and CC M/NC 3.244) and LTF (NAP/NC ratio log$_2$ 1.724, CC NM/NC 2.521 and CC M/NC 4.186) were increased in all disease conditions. HDGF is associated with CRC progression with cellular proliferation, migration, invasion, and tumorigenesis noticeably decreased in HCT116 and HT29 in vitro and in vivo HDGF knockdown models [39, 44]. LTF knockout resulted in inflammation-induced colorectal dysplasia in mice probably by inhibition of NF-κB and AKT/mTOR signaling suggesting a protective role in colorectal inflammation-related malignant transformation [40].

Metabolic functions of mitochondria are instrumental in tumor anabolism, oxidative stress, Ca$^{2+}$ homeostasis and cell death. [45]. Accumulation of dysfunctional mitochondria generates increased tumor-promoting reactive oxygen species (ROS) and tumorigenic signals [46]. Clearance of dysfunctional mitochondria via mitophagy is critical for cellular fitness [47]. A major trigger for mitochondrial clearance in tumor cells is mitochondrial membrane depolarization and hypoxia, activating PTEN-induced putative kinase 1 (PINK1)/Parkin pathway or through Bcl-2 [46]. Elevated mitochondrial fission by dynamin-related protein-1 (Drp1) recruitment leading to impaired cancer cell growth suggests its importance in tumorigenesis [48].

CAV-1 moderates lipid trafficking and is known to be up-regulated in drug resistant cancer cell lines [28] and in colon cancer, histone modifications bring about the genetic drift in CAV-1 gene regulation instead of DNA methylation [49], which agrees with the observations by Western blot analysis. CAV-1 plays an important role in cell migration and is a regulator of the K-RAS oncogene in colon carcinogenesis. It was demonstrated that colon tumor cells harboring K-RAS mutations had higher levels of CAV-1-1 mRNA levels involving the AKT pathway [50]. Paradoxically, decreased expression of CAV-1 has also been indicated as a potential prognostic factor for CRC [31, 51], which correlated with the proteomics results observed in this study with significant decrease from CC NM to CCM, but not NAP (NAP/NC ratio log$_2$ $-0.712$, CC NM/NC $-2.193$ and CC M/NC $-2.466$). CAVs are structural proteins forming 50- to 100-nm invaginations of the plasma membrane called caveolae that function as regulators of signal transduction. CAV-1 levels are positively correlated with tumor stage/grade in a number of cancer types and regulates multiple cancer-associated processes including cellular transformation, tumor growth, cell migration, cell death and survival, multidrug resistance and angiogenesis [52]. CAV-1 gene endogenous expression or re-expression may also reduce pancreatic carcinoma cell invasion probably through Erk-MMP signal pathway [53]. Furthermore, expression of CAV-1 in the ovarian carcinoma cell line OVCAR-3, resulted in suppression of tumor cell survival in vitro, suggesting that the CAV-1 gene is likely to act as a tumor-suppressor gene in human ovarian epithelium [54]. CRC patients with high stromal CAV-1 had a good (92%) 5-year survival rate, in contrast to patients with moderate levels or absent CAV-1 [54]. Overall, the complex role of CAV-1 in cancer explains the divergent results we have observed reflecting patient-to-patient variation in oncogenic events. Interestingly, β-actin was also observed to be decreased in colon proteomics results, whilst Western blotting results indicate a rise with early stage disease. As with CAV-1, there was significant patient variation, which may reflect tissue heterogeneity independent of cancer stage. One of the challenges of the studies using β-actin as a loading control is that β-actin is a protein itself and its expression varies from patient-to-patient just as with several other proteins. We reported our
observations which emphasize the fact that alternate loading control strategies should be followed instead of selecting patient proteins which are all altered in case of the colon cancer disease. We have screened a large number of patient tissues (n = 86) using western blotting that shows expression variations in different patients. This study is the first to report CAV-1 expression in non-malignant and malignant colon-specific tissues both by proteomics and by classical technique. There is evidence from our results that an increase in CAV-1 expression can differentiate non-metastatic cancer from normal, but this requires a more extensive study. Laser capture microdissection to isolate cancer cells would enable clarification of the expression variation in future studies.

Conclusions
With the incidence of CRC increasing worldwide at an alarming rate, it is important to discover patient-specific panel of prognostic factors and biomarkers for early detection and treatment. Proteomics provides the opportunity to screen changes in different tissues with pathologically altered proteome compared to the normal. Non-malignant and malignant tissues were selected to determine subtle changes at molecular level bringing about major shifts in disease state.

Despite genetic variations, there are proteins which are still common among colon cancer patients. Identifying the pool of differentially expressed proteins can be of meaningful significance in understanding the disease establishment. Our preliminary study has demonstrated the ability to undertake extensive quantitative proteomics analysis of individual small colon cancer biopsies (averaging 5 mm³) and gain an understanding of anatomically-specific disease progression. A number of proteins were up-regulated or down-regulated through stages of the disease, were associated with well-established characterisation of cancer progression and represent targets for further investigation. An ability to validate a known target in caveolin-1, served only to confirm seemingly contradictory evidence of increase and decrease in CRC that has been reported previously. In this study, we demonstrated that levels were stage-dependent, but also varied significantly from patient-to-patient. Nevertheless, the results have provided scope to explore new solutions in population profiling, such as microarray assays that will generate diagnostics for challenging environments such as those found in developing countries.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12014-019-9264-y.

Acknowledgements
We thank Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan for funding research of SS and Yorkshire Cancer Research for supporting the research of CS and SuS. Ethical approval was obtained from SKMCH&RC Internal Review Board and consent forms were signed by patients.

Authors’ contributions
SS contribution: Conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, revising it critically for important intellectual content, final approval of the version to be submitted. ST, IA and S contribution: Acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted. AA contribution: Acquisition of data, analysis and interpretation of data, final approval of the version to be submitted. MA contribution: Statistical analysis of data, final approval of the version to be submitted. SK, AAS, AHA, MH and MAY contribution: Acquisition of data, analysis and interpretation of data, revising the draft critically for important intellectual content, final approval of the version to be submitted. CS contribution: Design of the study, analysis and interpretation of data, drafting the article, revising it critically for important intellectual content. All authors read and approved the final manuscript.

Funding
This work was supported by Shaukat Khanum Memorial Cancer hospital and Research Center, Pakistan Chris Sutton and Sadirul Shaheed work is supported by Yorkshire Cancer Research, UK. They had no involvement in the study design and writing of article.

Availability of data and materials
We confirm that all the associated data to this study is available and can be produced at request. Most of the data is submitted as supporting material.

Ethics approval and consent to participate
The ethical approval of the study was obtained from Institutional Review Board (IRB) at Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan. The IRB/REC’s (IORG0004939) of SKMCH&RC is registered with the Office for Human Research Protections (OHRR) US Department of Health and Human Services. The informed consent of all participating subjects is obtained.

Consent for publication
We agree for publication upon acceptance and we agree that all copyright ownership for the article is transferred to—Clinical Proteomics (ISSN: 1559-0275). The material submitted is new, original and has not been submitted to another journal for concurrent consideration.

Competing interests
The authors declared that they have no competing interests.
Received: 12 August 2019   Accepted: 12 December 2019

References

1. Arnold M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2016;65(4):683–91.
2. Ng SC, Wong ST. Colorectal cancer screening in Asia. Br Med Bull. 2013;105:29–42.
3. Khan NA, et al. Dietary practices, addictive behavior and bowel habits and risk of early onset colorectal cancer: a case control study. Asian Pac J Cancer Prev. 2015;16(7):7967–73.
4. Huxley R, et al. The role of lifestyle risk factors on mortality from colorectal cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev. 2007;8(2):191–8.
5. Bhurgri Y, et al. Pakistan-country profile of cancer and cancer control 1995–2004. J Pak Med Assoc. 2006;56(3):124–30.
6. Akhtar F. Cancer registration in Pakistan: contemporary state of affairs. Asian Pac J Cancer Prev. 2007;8(3):452.
7. Bhurgri Y, et al. Cancer incidence in Karachi, Pakistan: first results from Karachi cancer registry. Int J Cancer. 2000;85(3):325–9.
8. Jamal S, Atique M, Khadim MT. Changing pattern of malignancies: analysis of histopathology based tumour registry data and comparison of three decades at Armed Forces Institute of Pathology, Rawalpindi, Pakistan. J Pak Med Assoc. 2014;64(1):24–7.
9. Anwar N, Badar F, Yusuf MA. Profile of patients with colorectal cancer at a tertiary care hospital in Karachi, Pakistan. Ann N Y Acad Sci. 2008;1138:199–203. https://doi.org/10.1196/annals.1414.026.
10. Badar F, et al. Epidemiology of cancers in Lahore, Pakistan, 2010–2012: a cross-sectional study. BMJ Open. 2016;6(6):e011828.
11. Álvarez-Chaver P, et al. Proteomics for discovery of candidate colorectal cancer biomarkers. WJG. 2014;20(14):3804–24.
12. Cristóbal A, et al. Personalized proteome profiles of healthy and tumor human colon organoids reveal both individual diversity and basic features of colorectal cancer. Cell Reports. 2017;18(1):263–74.
13. Krezet D, et al. Response profiling using shotgun proteomics enables global metallodrug mechanisms of action to be established. Chemistry. 2017;23(8):1881–90.
14. Wang JJ, et al. Comparative proteomics analysis of colorectal cancer. Asian Pac J Cancer Prev. 2012;13(4):1663–6.
15. Friedman DB, et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics. 2004;4(3):793–811.
16. Zhang B, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513(7518):382–3.
17. Ngoka LC. Sample prep for proteomics of breast cancer: proteomics and gene ontology reveal dramatic differences in protein solubilization preferences of radioimmunoprecipitation assay and urea lysis buffers. Proteome Sci. 2008;6:30.
18. Trowbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 1976;73(6):4350–4.
19. Chevalier S, Farsijani S. Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment. Appl Physiol Nutr Metab. 2014;39(6):643–53.
20. Inui A. Cancer anorexia-cachexia syndrome are neuropeptides the key? Cancer Res. 1999;59(18):4431–501.
21. Porporato PE. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 2016;5:e200.
22. Hartl WH, et al. Effect of glucagon on protein synthesis in human rectal cancer in situ. Ann Surg. 1998;227(3):390–7.
23. Le Tourneau C, Favre S, Raymond E. The role of integrins in colorectal cancer. Oncology (Williston Park). 2007;21(9 Suppl 3):21–4.
24. Wary KK, et al. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell. 1998;94(5):625–34.
25. Boujdadi S, et al. Integrin [alpha]1[beta]1 expression is controlled by c-MYC in colorectal cancer cells. Oncogene. 2016;35(13):1671–8.
26. McNicholl KM, et al. Characterization of changes in the proteome in different regions of 3D multicell tumor spheroids. J Proteome Res. 2012;11(5):2863–75.
27. Nunez-Wehinger S, et al. Caveolin-1 in cell migration and metastasis. Curr Mol Med. 2014;14(2):255–74.
28. Shatz M, Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer. Int J Radiat Biol. 2008;84(3):177–89.
29. Quest AE, et al. The caveolin-1 connection to cell death and survival. Curr Mol Med. 2013;13(2):266–81.
30. Zhao Z, et al. Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival. World J Gastroenterol. 2015;21(4):1140–7.
31. Bender FC, et al. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 2000;60(20):5870–8.
32. Chu D, et al. Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer. Ann Surg Oncol. 2012;19(1):318–25.
33. Kostova E, et al. Expression of matrix metalloproteinases 2, 7 and 9 in patients with colorectal cancer. Vojnosanit Pregl. 2014;71(1):52–9.
34. Hurst NG, et al. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasm in symptomatic patients. Br J Cancer. 2007;97(7):971–7.
35. Wilson S, et al. Serum matrix metalloproteinase 9 and colorectal neoplasm: a community-based evaluation of a potential diagnostic test. Br J Cancer. 2012;106(8):1431–8.
36. Bozzi F, et al. MIF/CD74 axis is a target for novel therapies in colon carcinomatis. J Exp Clin Cancer Res. 2017;36(1):16.
37. Messick CA, et al. CEACAM-7: a predictive marker for rectal cancer recurrence. Surgery. 2010;147(5):713–9.
38. Masoudi M, et al. Association between N142D genetic polymorphism of GSTO2 and susceptibility to colorectal cancer. Mol Biol Rep. 2011;38(7):4309–13.
39. Liao F, Dong W, Fan L. Apoptosis of human colorectal carcinoma cells concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer. 2007;97(7):971–7.
40. Wilson S, et al. Serum matrix metalloproteinase 9 and colorectal neoplasm: a community-based evaluation of a potential diagnostic test. Br J Cancer. 2012;106(8):1431–8.
41. Messick CA, et al. CEACAM-7: a predictive marker for rectal cancer recurrence. Surgery. 2010;147(5):713–9.
42. Honeywell RJ, et al. DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors. Nucleosides Nucleotides Nucleic Acids. 2018;37(12):696–708.
43. Ramkumar K, et al. Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor. Nat Commun. 2016;7:13084.
44. Lian J, et al. Positive feedback loop of hepatoma-derived growth factor and c-MET in colorectal cancer. Ann N Y Acad Sci. 2010;1274:1219–26.
45. Ye Q, et al. Lactoferrin deficiency promotes colitis-associated colorectal dysplasia in mice. PLoS ONE. 2014;9(7):e103298.
46. Charrasse S, et al. Characterization of the cDNA and pattern of expression of a new gene over-expressed in human hepatomas and colonic tumors. Eur J Biochem. 1995;234(2):406–13.
47. Honeywell RJ, et al. DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors. Nucleosides Nucleotides Nucleic Acids. 2018;37(12):696–708.
48. Ramkumar K, et al. Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor. Nat Commun. 2016;7:13084.
49. Lian J, et al. Positive feedback loop of hepatoma-derived growth factor and beta-catenin promotes carcinogenesis of colorectal cancer. Oncotarget. 2015;6(30):29357–74.
50. Porporato PE, et al. Mitochondrial metabolism and cancer. Cell Res. 2017;27:265.
51. Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;166(3):555–66.
47. Mancias JD, Kimmelman AC. Mechanisms of selective autophagy in normal physiology and cancer. J Mol Biol. 2016;428(9):1659–80.
48. Mishra P, Chan DC. Metabolic regulation of mitochondrial dynamics. J Cell Biol. 2016;212(4):379–87.
49. Deb M, et al. Epigenetic drift towards histone modifications regulates CAV1 gene expression in colon cancer. Gene. 2016;581(1):75–84.
50. Basu Roy UK, et al. Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis. Int J Cancer. 2013;133(1):43–57.
51. Zhao Z, et al. Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival. WJG. 2015;21(4):1140–7.
52. Nohata N, et al. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol. 2011;38(1):209–17.

53. Han F, Zhu H-G. Caveolin-1 regulating the invasion and expression of matrix metalloproteinase (MMPs) in pancreatic carcinoma cells. J Surg Res. 2010;159(1):443–50.
54. Wiechen K, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 2001;159(5):1635–43.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.